So many women in their 40s and 50s are trying to make informed decisions about their health, only to be met with outdated warnings, mixed messages, or advice that dismisses their very real symptoms. In this episode, Dr. Jessica Ritch breaks down the huge updates shaping the future of menopause care — including the FDA’s newly revised stance on estrogen, the shift toward earlier perimenopause treatment, advancements in personalized hormone therapy, and new insights from the 2025 Menopause Soci...
All content for EnRitched Menopause is the property of Jessica Ritch, MD and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
So many women in their 40s and 50s are trying to make informed decisions about their health, only to be met with outdated warnings, mixed messages, or advice that dismisses their very real symptoms. In this episode, Dr. Jessica Ritch breaks down the huge updates shaping the future of menopause care — including the FDA’s newly revised stance on estrogen, the shift toward earlier perimenopause treatment, advancements in personalized hormone therapy, and new insights from the 2025 Menopause Soci...
Hormone therapy can have a lot of benefits, but there are risks, too and it’s not right for everyone. In this episode, Dr. Ritch discusses the main reasons why someone shouldn’t be on hormone therapy and areas to consider the risks versus benefits. She discusses everything from cancer to heart disease, family history and genetic factors, migraine headaches and more. ---------------- Ready to enrich your menopause journey? Connect with Dr. Jessica Ritch through Facebook, Inst...
EnRitched Menopause
So many women in their 40s and 50s are trying to make informed decisions about their health, only to be met with outdated warnings, mixed messages, or advice that dismisses their very real symptoms. In this episode, Dr. Jessica Ritch breaks down the huge updates shaping the future of menopause care — including the FDA’s newly revised stance on estrogen, the shift toward earlier perimenopause treatment, advancements in personalized hormone therapy, and new insights from the 2025 Menopause Soci...
